Medidata predicts its new mobile app will speed study start-up and improve participant experience.
The Dassault Systèmes owned-company launched the application – which is called myMedidata- this month, explaining the aim is to provide trial participants with a single login for all their remote clinical trial activities.
Matt Noble, senior vice president, Medidata Patient Cloud, said “our latest addition to myMedidata brings an innovative app to patients designed in concert with our patient insights team, customer feedback, and the experiences derived from running the world’s biggest decentralized clinical trials (DCTs) over the last twenty years.
He added that “Medidata is leveraging its unique insights from sponsors, CROs, sites, and patients to make a meaningful difference in the clinical trial experience.”
Tech platform
The new app is part of Medidata’s wider suite of applications. Like the others it is available on iOS and Android systems and can be used both on the patients’ own devices or those provided by those running drug studies.
Also, like other Medidata applications, the new application can be set-up using the firm’s configuration technology – called Designer – which is designed to let sponsors and clinical research organizations (CRO) partners build systems.
According to Medidata “designer drastically lowers study build times by employing Medidata and client libraries, including pre-built eCOA instruments, translations, and study configurations.”
Patient experience
The app launch follows less than a year after Medidata granted CROs and trial sites access to its “patient insights” program and study design systems.
At the time Medidata said the idea is to let CROs work with Medidata researchers to develop protocols and “patient-facing” solutions to improve clinical trial experiences and expedite development and delivery timelines.
It also comes after Medidata partnered with Parexel in a bid to improve patient access to remote studies in keeping with growing industry interest in decentralized study models.
Unsplash/AndyHermawan